Protocol Ledger

NCT04167670 · Phase III · COMPLETED

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

Interventional Phase III clinical trial protocol NCT04167670 sponsored by Phathom Pharmaceuticals in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-10 Enrollment: 1,046 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04167670
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,046 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04167670
Protocol FieldVerified Registry Value
NCT IdentifierNCT04167670
Consolidated Lead SponsorPhathom Pharmaceuticals
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,046 participants (ACTUAL)
Registered Start Date2019-12-10
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI